Supernus Pharmaceuticals received approval from the FDA for Oxtellar XR (oxcarbazepine extended-release tablets) for use as adjunctive therapy in the treatment of partial seizures in adults and in children 6–17 years of age.
Oxtellar XR is a novel once-daily extended release formulation of oxcarbazepine (formerly known as SPN-804).
The product will be available as 150mg, 300mg and 600mg extended-release tablets in 100-count bottles. Oxtellar XR is expected to launch in the first quarter of 2013.
For more information call (301) 838-2500 or visit www.supernus.com.